FDA Approves First GLP-1 Generic for Weight Loss

August 29, 2025

The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceuticals’ generic version of Novo Nordisk’s Saxenda (liraglutide), a first-generation glucagon-like peptide-1 (GLP-1) receptor agonist. The generic is approved to treat adults and adolescents 12 to 17 years of age who are obese or overweight. This is the first time a generic glucagon-like peptide-1 receptor agonist (GLP-1RA) medication has been approved for weight loss in the US.

Read more at Reuters >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • AMA Urges HHS to Withdraw Proposal Expanding Access to Certain Unapproved Peptides
    • Health Canada Warns Against Unauthorized Peptides After Bacteria Found in Seized Products
    • FDA Authorizes Clinical Trials Evaluating Lynch Regenerative Medicine’s rhPDGF-BB for Facial Skin Quality and Infraorbital Hollows
    • Hims & Hers Launches Peptides+ for Men
    • Alpha Aesthetics Partners Launches Clinical Education for Platform Practices